Rapportage bias in onderzoeken naar de werkzaamheid van tweede generatie antidepressiva in de behandeling van een gegeneraliseerde angststoornis en een obsessief-compulsieve stoornis in kinderen.

Douma, Myrthe (2023) Rapportage bias in onderzoeken naar de werkzaamheid van tweede generatie antidepressiva in de behandeling van een gegeneraliseerde angststoornis en een obsessief-compulsieve stoornis in kinderen. Master thesis, Psychology.

Text Thesis_Myrthe Elise Douma_S3433331 (4).docx.pdf Restricted to Registered users only Download (364kB)

Abstract

Importance: The study by Roest et al. (2015) has shown that scientific literature overestimates the efficacy of second-generation antidepressants in adults with an anxiety disorder. However, indications regarding to children with anxiety disorders for these drugs are not yet known. Objective: To investigate biases in reporting in double-blind, placebo-controlled studies of the pharmacological treatment of generalized anxiety disorders and obsessive- compulsive disorders in children and quantify the extent to which these biases inflation estimates of drug efficacy. Data source and study selection: There were reviews obtained from the US Food and Drug Administration (FDA) for trials of 4 second-generation antidepressants in the treatment of generalized anxiety disorders and obsessive-compulsive disorders. A systematic search for matching publications was performed using PsycINFO and Medline. The number of citations was examined in the Web of Science Core Collection. Main outcomes and measures: Reporting bias was examined and categorized as study publication bias, outcome reporting bias and spin (abstract conclusions inconsistent with published primary endpoint results). The number of citations was examined by looking at how many citations one published article had. Results: The findings of all of the 4 trials where positive according to the FDA. This matched with the published literature, where all of the 4 trials were positive. Because all trials were found to be positive according to the FDA, there was no study publication bias. Conclusions and relevance: There were no kind of reporting biases present for trials on the efficacy of FDA-approved second-generation antidepressants for anxiety disorders and obsessive-compulsive disorders in children. Even though there was no study publication bias, it is still important to remain critical when using the FDA reports, because these reports have a number of limitations.

Item Type:	Thesis (Master)
Supervisor name:	Roest, A.M.
Degree programme:	Psychology
Differentiation route:	Ontwikkelingspsychologie (O) [Master Psychology]
Date Deposited:	24 Feb 2023 14:42
Last Modified:	24 Feb 2023 14:42
URI:	http://gmwpublic.studenttheses.ub.rug.nl/id/eprint/1742

Actions (login required)

View Item